OncoSec Medical Inc (ONCS) : Ridgeback Capital Investments added new position in OncoSec Medical Inc during the most recent quarter end. The investment management firm now holds 1,292,614 shares of OncoSec Medical Inc which is valued at $2,249,148 , the company said in a statement filed on Aug 12, 2016 with the SEC.OncoSec Medical Inc makes up approximately 16.42% of Ridgeback Capital Investments’s portfolio.
Other Hedge Funds, Including , Renaissance Technologies boosted its stake in ONCS in the latest quarter, The investment management firm added 79,800 additional shares and now holds a total of 123,200 shares of OncoSec Medical Inc which is valued at $214,368.Vanguard Group Inc boosted its stake in ONCS in the latest quarter, The investment management firm added 13,025 additional shares and now holds a total of 430,031 shares of OncoSec Medical Inc which is valued at $748,254. Acrospire Investment Management added ONCS to its portfolio by purchasing 1,112 company shares during the most recent quarter which is valued at $2,124.
OncoSec Medical Inc closed down -0.015 points or -0.88% at $1.685 with 50,096 shares getting traded on Monday. Post opening the session at $1.7, the shares hit an intraday low of $1.68 and an intraday high of $1.72 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on OncoSec Medical Inc. Rodman & Renshaw Resumed OncoSec Medical Inc on Jul 21, 2016 to “Buy”, Price Target of the shares are set at $6.
OncoSec Medical Incorporated is a biotechnology company focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types. The Company’s technology includes property relating to its ImmunoPulse delivery technology. The Company’s ImmunoPulse is an electroporation delivery device that the Company uses in combination with its therapeutic product candidates including deoxyribonucleic acid (DNA) plasmids that encode for immunologically active agents to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. Its electroporation devices consist of an electrical pulse generator and disposable applicators. The Company’s ImmunoPulse product candidates are based on its DNA based immunotherapy technology.